Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM3 | P20309 | 7/20 | 0.50 |
| ▸ | DRD1 | P21728 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.42 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.42 |
| ▸ | BRD4 | O60885 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2277788 | 0.84 | KDM4E (0.47) | HTR2ASIGMAR1KDM4EATMBRD4 | |
| SCHEMBL2270924 | 0.83 | HTR7 (0.44) | HTR2AKDM4EATMBRD4 | |
| SCHEMBL2269413 | 0.78 | KDM4E (0.49) | DRD1HTR2ASIGMAR1KDM4EATM | |
| SCHEMBL28740554 | 0.77 | BRD4 (0.52) | HTR2ABRD4 | |
| SCHEMBL2273802 | 0.76 | HTR2A (0.53) | CHRM3HTR2AKDM4EATM | |
| SCHEMBL15118589 | 0.76 | BRD4 (0.54) | CHRM3HTR2ABRD4 | |
| SCHEMBL15829965 | 0.74 | DRD2 (0.60) | DRD1HTR2A | |
| SCHEMBL15830146 | 0.74 | KDM4E (0.54) | SIGMAR1KDM4EATM | |
| SCHEMBL10212349 | 0.74 | KDM4E (0.54) | SIGMAR1KDM4EATM | |
| SCHEMBL2279377 | 0.73 | HTR2C (0.49) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | claimed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | claimed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | claimed |
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-8957059-B2 | Modulators of serotonin receptors | JANSSEN PHARMACEUTICA NV (BG) | 2015-02-17 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | JANSSEN PHARMACEUTICA NV (US) | 2014-02-06 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-8575364-B2 | Modulators of serotonin receptor | JANSSEN PHARMACEUTICA NV (BE) | 2013-11-05 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2011-08-25 | — | — | US | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
| WO-2010059390-A1 | MODULATORS OF SEROTONIN RECEPTOR | JANSSEN PHARMACEUTICA NV (BE) | 2010-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140038934-A1 | MODULATORS OF SEROTONIN RECEPTORS | HTR1A, HTR2A, HTR6 | CHRM3 136/4885DRD1 327/4885HTR2A 2/4885 |
| US-20110207709-A1 | MODULATORS OF SEROTONIN RECEPTOR | HTR1A, HTR6, HTR2A | CHRM3 135/4885DRD1 301/4885HTR2A 3/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.